Figure - available from: Nature Communications
This content is subject to copyright. Terms and conditions apply.
Fructose-1,6-biphosphate (F16BP), a glycolytic metabolite, can be formulated into microparticles (MPs)
a Schematic representation of F16BP MPs rescuing dendritic cells (DCs) from glycolytic inhibition. b Scanning electron microscopy-energy dispersive X-ray analysis (SEM-EDX) mapping demonstrating the presence of Ca and P in the microparticles. c Scanning electron microscopy image indicating spherical morphology. d Dynamic light scattering (DLS) suggests a size of 2200 ± 300 nm of F16BP MPs.

Fructose-1,6-biphosphate (F16BP), a glycolytic metabolite, can be formulated into microparticles (MPs) a Schematic representation of F16BP MPs rescuing dendritic cells (DCs) from glycolytic inhibition. b Scanning electron microscopy-energy dispersive X-ray analysis (SEM-EDX) mapping demonstrating the presence of Ca and P in the microparticles. c Scanning electron microscopy image indicating spherical morphology. d Dynamic light scattering (DLS) suggests a size of 2200 ± 300 nm of F16BP MPs.

Source publication
Article
Full-text available
Inhibition of glycolysis in immune cells and cancer cells diminishes their activity, and thus combining immunotherapies with glycolytic inhibitors is challenging. Herein, a strategy is presented where glycolysis is inhibited in cancer cells using PFK15 (inhibitor of PFKFB3, rate-limiting step in glycolysis), while simultaneously glycolysis and func...

Citations

... Normally, cells undergo aerobic oxidation through the tricarboxylic acid (TCA) cycle in the presence of sufficient oxygen, thereby generating a substantial amount of energy [9]. However, in an environment with low oxygen levels, the TCA cycle is suppressed, prompting tumor cells to rely on glycolysis for energy production [50]. This metabolic shift can result in the production of substantial quantities of lactate, which serves to further exacerbate the acidification of the tumor microenvironment. ...
... Conversely, under conditions of hypoxia or during high-intensity exercise, cells rely on glycolysis to produce lactate as a rapid source of energy [20,21]. Notably, the excessive accumulation of lactate has been closely associated with the pathogenesis and progression of various diseases, including liver disorders, tumors, and cardiovascular diseases [50,71,82,96]. Therefore, a comprehensive understanding of lactate metabolism and its implications in disease processes is crucial for developing novel therapeutic strategies. ...
Preprint
Full-text available
Lactate plays a critical role in cell metabolism and disease development. Under conditions of hypoxia or high-intensity exercise, cells use the glycolytic pathway to convert glucose into pyruvate, which is then reduced to lactate to quickly obtain energy. The traditional role of lactate is being redefined, as it is not only a provider of energy but also an important signaling molecule that regulates cell physiological functions, including histone lactylation modification, which affects gene expression. However, excessive accumulation of lactate is associated with the development of various diseases, such as liver disease, cancer, and cardiovascular disease. Research has also found that small-molecule drugs can regulate lactate levels, providing new possibilities for treating related diseases.
... SIRT1 is a key regulator of canonical metabolic pathways in BMDCs Sirtuin 1 (SIRT1) acts by regulating different targets related to metabolism [23,24], in caloric restriction and obesity animal models [25]. Additionally, the pro-inflammatory profile observed in our previous experiments has been correlated with both glycolysis [26,27] and oxidative phosphorylation (OXPHOS) [27][28][29]. However, so far, these canonical metabolic pathways in dendritic cells (DCs) were not correlated with SIRT1 in obesity. ...
Article
Full-text available
Sirtuin 1 (SIRT1) is a class III histone deacetylase (HDAC3) that plays a crucial role in regulating the activation and differentiation of dendritic cells (DCs) as well as controlling the polarization and activation of T cells. Obesity, a chronic inflammatory condition, is characterized by the activation of immune cells in various tissues. We hypothesized that SIRT1 might influence the phenotype and functions of DCs through the Ido1 pathway, ultimately leading to the polarization towards pro-inflammatory T cells in obesity. In our study, we observed that SIRT1 activity was reduced in bone marrow-derived DCs (BMDCs) from obese animals. These BMDCs exhibited elevated oxidative phosphorylation (OXPHOS) and increased extracellular acidification rates (ECAR), along with enhanced expression of class II MHC, CD86, and CD40, and elevated secretion of IL-12p40, while the production of TGF-β was reduced. The kynurenine pathway activity was decreased in BMDCs from obese animals, particularly under SIRT1 inhibition. SIRT1 positively regulated the expression of Ido1 in DCs in a PPARγ-dependent manner. To support these findings, ATAC-seq analysis revealed that BMDCs from obese mice had differentially regulated open chromatin regions compared to those from lean mice, with reduced chromatin accessibility at the Sirt1 genomic locus in BMDCs from obese WT mice. Gene Ontology (GO) enrichment analysis indicated that BMDCs from obese animals had disrupted metabolic pathways, including those related to GTPase activity and insulin response. Differential expression analysis showed reduced levels of Pparg and Sirt1 in BMDCs from obese mice, which was challenged and confirmed using BMDCs from mice with conditional knockout of Sirt1 in dendritic cells (SIRT1∆). This study highlights that SIRT1 controls the metabolism and functions of DCs through modulation of the kynurenine pathway, with significant implications for obesity-related inflammation.
... Glycolysis is essential for both activation of DCs, which mediate T cell activation. Instead of complex genetic upregulation of glucose transporters and glycolysis 104 The strategy realized specific inhibition of glycolysis in tumor cells and replenished substrates for DC-targeting glycolysis, thus efficiently activating anti-tumor immunity. Through the same approach, exhausted T cells in the TME can be rescued via targeted delivery of critical substrates. ...
... One of the most significant effects of aerobic glycolysis is the acidification of the TME due to lactate secretion [197,198], which supports increased migration and invasion [199] and promotes immune reprogramming towards a tolerant phenotype [196,200]. Glycolysis in the tumour stroma is also required for adequate antitumoral response, which has led to the development of metabolite-based formulations in the presence of a glycolytic inhibitor that specifically targets cancer cells [201]. Cancer and T cells compete for glucose among several other metabolites, and the avidity of cancer cells for this nutrient diminishes the cytolytic activity [195,202,203]. ...
Article
Full-text available
Prostate cancer is one of the most commonly diagnosed cancers in men and is a major cause of cancer-related deaths worldwide. Among the molecular processes that contribute to this disease, the weight of metabolism has been placed under the limelight in recent years. Tumours exhibit metabolic adaptations to comply with their biosynthetic needs. However, metabolites also play an important role in supporting cell survival in challenging environments or remodelling the tumour microenvironment, thus being recognized as a hallmark in cancer. Prostate cancer is uniquely driven by androgen receptor signalling, and this knowledge has also influenced the paths of cancer metabolism research. This review provides a comprehensive perspective on the metabolic adaptations that support prostate cancer progression beyond androgen signalling, with a particular focus on tumour cell intrinsic and extrinsic pathways.
... To investigate the targeting ability of aptPD-L1 or eCpG in TME under clinically relevant conditions in vitro, we synthesized aptPD-L1 or eCpG with fluorescent 5'-FAM tags, thus allowing the accurate profiling of the cellular distribution of the aptamer species in the B16F10/splenocyte co-incubation system. Concrete evidence confirms that B16F10 cells have strong similarities with human melanoma cells in terms of upregulated PD-L1, VEGF, and HIF-1α expression 58 , hyperglycolysis metabolism trait 59 and pathological traits including high invasiveness and metastasis risk 60,61 , which is a widely used model system in melanoma research. Flow cytometric results immediately suggested that the amount of aptPD-L1 bound to B16F10 cell surface was 410% higher than splenocytes, which was in line with the elevated PD-L1 expression status of melanoma cells compared with their normal counterparts or immune cells (Fig. 3a). ...
Article
Full-text available
Radio-immunotherapy exploits the immunostimulatory features of ionizing radiation (IR) to enhance antitumor effects and offers emerging opportunities for treating invasive tumor indications such as melanoma. However, insufficient dose deposition and immunosuppressive microenvironment (TME) of solid tumors limit its efficacy. Here we report a programmable sequential therapeutic strategy based on multifunctional fusogenic liposomes (Lip@AUR-ACP-aptPD-L1) to overcome the intrinsic radio-immunotherapeutic resistance of solid tumors. Specifically, fusogenic liposomes are loaded with gold-containing Auranofin (AUR) and inserted with multivariate-gated aptamer assemblies (ACP) and PD-L1 aptamers in the lipid membrane, potentiating melanoma-targeted AUR delivery while transferring ACP onto cell surface through selective membrane fusion. AUR amplifies IR-induced immunogenic death of melanoma cells to release antigens and damage-associated molecular patterns such as adenosine triphosphate (ATP) for triggering adaptive antitumor immunity. AUR-sensitized radiotherapy also upregulates matrix metalloproteinase-2 (MMP-2) expression that combined with released ATP to activate ACP through an “and” logic operation-like process (AND-gate), thus triggering the in-situ release of engineered cytosine-phosphate-guanine aptamer-based immunoadjuvants (eCpG) for stimulating dendritic cell-mediated T cell priming. Furthermore, AUR inhibits tumor-intrinsic vascular endothelial growth factor signaling to suppress infiltration of immunosuppressive cells for fostering an anti-tumorigenic TME. This study offers an approach for solid tumor treatment in the clinics.
... Type I IFN facilitate a continued commitment to this metabolic state through the NOS2 axis, a process dependent on the NAD+ metabolome [50]. The metabolites from glycolysis and the associated pentose phosphate pathway are used in various biosynthetic pathways, and suppression of glycolic metabolism in DC has been shown to drive innate immune dysfunction and enhance viral replication [41,[51][52][53]. This suggests an intimate link between cellular metabolism and establishment of an innate immune-cell-driven antiviral state. ...
Article
Full-text available
Previous studies from our laboratory and others have established the dendritic cell (DC) as a key target of RSV that drives infection-induced pathology. Analysis of RSV-induced transcriptomic changes in RSV-infected DC revealed metabolic gene signatures suggestive of altered cellular metabolism. Reverse phase protein array (RPPA) data showed significantly increased PARP1 phosphorylation in RSV-infected DC. Real-time cell metabolic analysis demonstrated increased glycolysis in PARP1-/- DC after RSV infection, confirming a role for PARP1 in regulating DC metabolism. Our data show that enzymatic inhibition or genomic ablation of PARP1 resulted in increased ifnb1, il12, and il27 in RSV-infected DC which, together, promote a more appropriate anti-viral environment. PARP1-/- mice and PARP1-inhibitor-treated mice were protected against RSV-induced immunopathology including airway inflammation, Th2 cytokine production, and mucus hypersecretion. However, delayed treatment with PARP1 inhibitor in RSV-infected mice provided only partial protection, suggesting that PARP1 is most important during the earlier innate immune stage of RSV infection.
... Indeed, murine studies suggest that augmenting DC numbers alone is sufficient to activate anti-tumour immunity [34,117]. However, with our growing understanding of the dominant suppressive nature of the TME is an awareness that, in addition to increasing DCs numbers, we may need strategies to directly remodel the local tumour environment to enhance DC activation and metabolism [99,118]. An exciting new perspective has arisen from work by the Reis e Sousa lab demonstrating that tumours exploit the systemic actin scavenging system to prevent cross-presentation of tumour antigens by DCs via DNGR1/Clec9a [36]. ...
Article
Full-text available
The concept of a therapeutic cancer vaccine to activate anti-tumour immunity pre-dates innovations in checkpoint blockade immunotherapies. However, vaccination strategies have yet to show the hoped-for successes in patients, and unanswered questions regarding the underlying immunological mechanisms behind cancer vaccines have hampered translation to clinical practice. Recent advances in our understanding of the potential of tumour mutational burden and neo-antigen-reactive T cells for response to immunotherapy have re-ignited enthusiasm for cancer vaccination strategies, coupled with the development of novel mRNA-based vaccines following successes in prevention of COVID-19. Here we summarise current developments in cancer vaccines and discuss how advances in our comprehension of the cellular interplay in immunotherapy-responsive tumours may inform better design of therapeutic cancer vaccines, with a focus on the role of dendritic cells (DCs) as the orchestrators of anti-tumour immunity. The increasing number of clinical trials and research being funnelled into cancer vaccines has demonstrated the ‘proof-of-principle’, supporting the hypothesis that therapeutic vaccines have potential as an immuno-oncology agent. For efficacious and safe cancer vaccines to be developed, better understanding of the underpinning immunological mechanisms is paramount.
Article
Full-text available
Metabolism, including glycolysis, oxidative phosphorylation, fatty acid oxidation, and other metabolic pathways, impacts the phenotypes and functions of immune cells. The metabolic regulation of the immune system is important in the pathogenesis and progression of numerous diseases, such as cancers, autoimmune diseases and metabolic diseases. The concept of immunometabolism was introduced over a decade ago to elucidate the intricate interplay between metabolism and immunity. The definition of immunometabolism has expanded from chronic low-grade inflammation in metabolic diseases to metabolic reprogramming of immune cells in various diseases. With immunometabolism being proposed and developed, the metabolic regulation of the immune system can be gradually summarized and becomes more and more clearer. In the context of many diseases including cancer, autoimmune diseases, metabolic diseases, and many other disease, metabolic reprogramming occurs in immune cells inducing proinflammatory or anti-inflammatory effects. The phenotypic and functional changes of immune cells caused by metabolic regulation further affect and development of diseases. Based on experimental results, targeting cellular metabolism of immune cells becomes a promising therapy. In this review, we focus on immune cells to introduce their metabolic pathways and metabolic reprogramming, and summarize how these metabolic pathways affect immune effects in the context of diseases. We thoroughly explore targets and treatments based on immunometabolism in existing studies. The challenges of translating experimental results into clinical applications in the field of immunometabolism are also summarized. We believe that a better understanding of immune regulation in health and diseases will improve the management of most diseases.